Related Experiment Video

Updated: Jun 2, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

Application of small interfering RNAs and drug combination for pancreatic cancer therapy

Chaoyang Zeng1, Shu-Zhen Chen1,2

  • 1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

Journal of Drug Targeting
|May 31, 2026
PubMed

Insights

Small interfering RNAs (siRNAs) show promise for pancreatic cancer treatment by silencing critical genes and enhancing chemotherapy and immunotherapy efficacy. This review highlights siRNAs as a potential breakthrough in combating this deadly disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • RNA Therapeutics

Background:

  • Pancreatic cancer is a leading cause of cancer-related mortality.
  • Gene expression alterations are crucial in pancreatic cancer development.
  • Small interfering RNAs (siRNAs) offer targeted gene silencing for therapeutic applications.

Purpose of the Study:

  • To review the potential of siRNA-based therapies for pancreatic cancer.
  • To explore siRNA's role in gene silencing, drug resistance, and immunotherapy enhancement.
  • To assess the combined efficacy of siRNAs with conventional treatments.

Main Methods:

  • Review of current literature on siRNA applications in pancreatic cancer.
  • Analysis of siRNA's mechanism in targeting oncogenic genes (e.g., K-Ras).
  • Evaluation of siRNA's impact on drug resistance and immunotherapy.

Main Results:

  • siRNAs can effectively silence key genes involved in pancreatic cancer progression.
  • siRNAs can overcome chemoresistance by targeting relevant genes.
  • siRNAs demonstrate potential in augmenting immunotherapy effectiveness.

Conclusions:

  • siRNA technology presents a promising therapeutic strategy for pancreatic cancer.
  • Combination therapy with siRNAs and chemical or immunological agents may significantly improve patient outcomes.
  • Further research into siRNA delivery systems is essential for clinical translation.
Keywords:
Pancreatic cancerchemotherapeutic drugsimmunotherapynanoparticlessiRNAs

More Related Videos

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Small interfering RNAs (siRNA)02:30

Small interfering RNAs (siRNA)

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...